2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N11772
    Mutanocyclin 875455-92-8 99.94%
    Mutanocyclin is a potent antifungal agent. Mutanocyclin inhibits Candida albicans (C. albicans) filamentation. Mutanocyclin decreases the mRNA expression of HWP1, ECE1, FLO8, TEC1. Mutanocyclin inhibits yeast-form in ex vivo mouse.
    Mutanocyclin
  • HY-N11911
    Verazine 14320-81-1 ≥99.0%
    Verazine ((-)-Verazine) is an anti-Fungal Agent that can be found in the dried roots and rhizoma of Veratrum maackii Regel. Verazine causes DNA damage in the cerebellum and cerebral cortex of mice in a dose-dependent manner. Verazine can be used in the study of fungal infections and neurological diseases.
    Verazine
  • HY-N12240
    Oleanolic aldehyde 17020-22-3 99.84%
    Oleanolic aldehyde is an antimicrobial compound used to inhibit oral bacteria. Oleanolic aldehyde inhibits Streptococcus mutans and Porphyromonas gingivalis, which are associated with dental caries and periodontal disease, with minimum inhibitory concentrations (MICs) of 488 μg/mL and 250 μg/mL, respectively.
    Oleanolic aldehyde
  • HY-N1415R
    β-Caryophyllene (Standard) 87-44-5 98.78%
    β-Caryophyllene (Standard) is the analytical standard of β-Caryophyllene. This product is intended for research and analytical applications. β-Caryophyllene is a CB2 receptor agonist.
    β-Caryophyllene (Standard)
  • HY-N1584C
    Halofuginone lactate 82186-71-8 98.32%
    Halofuginone lactate, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone lactate is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone lactate is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone lactate has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.
    Halofuginone lactate
  • HY-N1778A
    (E)-3,4-Dimethoxycinnamic acid 14737-89-4 99.91%
    (E)-3,4-Dimethoxycinnamic acid is the less active isomer of 3,4-Dimethoxycinnamic acid. 3,4-Dimethoxycinnamic acid exerts anti-apoptotic effects on L-02 cells via the ROS-mediated signaling pathway. Anti-apoptotic effects.
    (E)-3,4-Dimethoxycinnamic acid
  • HY-N1944A
    cis-Nerolidol 3790-78-1
    cis-Nerolidol is a sesquiterpene alcohol that can be found in various plants. cis-Nerolidol exhibits antioxidant and antibacterial activities. cis-Nerolidol can also potentiate the action of antibiotics.
    cis-Nerolidol
  • HY-N6952R
    Geraniol (Standard) 106-24-1
    Geraniol (Standard) is the analytical standard of Geraniol. This product is intended for research and analytical applications. Geraniol, an olefinic terpene, was found to inhibit growth of Candida albicans and Saccharomyces cerevisiae strains.
    Geraniol (Standard)
  • HY-N7144A
    Citronellyl acetate 150-84-5 ≥98.0%
    Citronellyl acetate is a monoterpene product of the secondary metabolism of plants, with antinociceptive activity. Citronellyl acetate exhibits pro-apoptotic activity in human hepatoma cells. Citronellyl acetate shows fungicidal, larvicidal, bactericidal and repelling/insecticidal effects.
    Citronellyl acetate
  • HY-P1508A
    Bactenecin TFA 98.42%
    Bactenecin TFA (Bactenecin, bovine TFA) is a potent 12-aa looped antimicrobial peptide isolated from bovine neutrophils. Bactenecin TFA inhibits the growth of bacteria and yeast, and kills the fungus Trichophyton rubrum. Bactenecin TFA increass membrane permeability, inhibits the growth and biofilm formation of B. pseudomallei.
    Bactenecin TFA
  • HY-P1783A
    M2e, human TFA 99.86%
    M2e, human TFA, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A. M2e, human TFA is a valid and versatile vaccine candidate to protect against any strain of human influenza A.
    M2e, human TFA
  • HY-P99309
    Pagibaximab 595566-61-3 98.81%
    Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis.
    Pagibaximab
  • HY-P99425
    Afelimomab 156227-98-4
    Afelimomab (MAK 195F) is an anti-tumor necrosis factor F(ab')2 monoclonal antibody fragment. Afelimomab can be used for the research of sepsis.
    Afelimomab
  • HY-P99551
    Tosatoxumab 1374419-41-6
    Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent.
    Tosatoxumab
  • HY-P99571
    Tefibazumab 521079-87-8 99.90%
    Tefibazumab is a humanized IgG1κ monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A. Tefibazumab can be used for the research of serious Staphylococcus aureus infections.
    Tefibazumab
  • HY-P99584
    Suvizumab 914257-21-9 ≥99.0%
    Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection.
    Suvizumab
  • HY-P99686
    Larcaviximab 1792982-56-9
    Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody.
    Larcaviximab
  • HY-P99703
    Libivirumab 569658-79-3 98.27%
    Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively.
    Libivirumab
  • HY-P99811
    Rafivirumab 944548-37-2
    Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails.
    Rafivirumab
  • HY-Y0366S
    Lauric acid-13C 93639-08-8 99.80%
    Lauric acid-13C is the 13C labeled Lauric acid. Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
    Lauric acid-13C
Cat. No. Product Name / Synonyms Application Reactivity